Category: Hydroxychloroquine

Dr. Vladimir Zelenko Interview

Dr. Vladimir Zelenko talks with author John Leake about treating his patients for Covid-19 and then sharing his insight with the White House. In spite of (or because of) President Trump’s initial embrace of Dr. Zelenko’s treatment protocol, government agencies such as the NIH and FDA first dismissed it, and then prevented public access to its key ingredient, hydroxychloroquine. This deliberate suppression of a life saving medication led to the preventable deaths of hundreds of thousands of Americans.

Read More »

A Conversation With Dr. Brian Tyson – The Chloroquine Wars Part XLI

The data from the vaccine trials must be recalculated under the lens that some of the serious adverse events (SAEs) should be treated as COVID-19 cases.
There may not be any vaccine efficacy in the data at all if some of the post-vaccination deaths are due to vaccine-induced COVID-19. It could even be the case that the mortality efficacy goes negative. My implied lives saved calculations put this easily in the realm of possibility. The only way to know is for authorities to organize and compile the data. And while a risk analysis is certainly due after more than six months of hundreds of millions of doses delivered, there is little indication authorities have bothered with the process. That’s more than a bit unsettling.

Read More »

Dr. Brian Tyson, USA: Hydroxychloroquine – Data, Strategies and Success Treating over 6000 Covid Patients

We continue to delve extensively into the COVID-19 data with esteemed statistician, Mathew Crawford. In this episode, we take a closer look at the use of early treatment and its success. Mathew has been researching the data from Dr. Brian Tyson, who has successfully treated over 6000 patients who contracted COVID throughout the pandemic. It is my great honor to have Dr. Tyson here on this episode to not only discuss the data, but also the strategies that he has been using throughout the pandemic.

Read More »

The Meta-Analytical Fixers: An Ivermectin Tale – The Chloroquine Wars Part XL

The Roman/Hernandez meta-analysis comes at a politically contentious moment. Their language and behavior appear political. Their work is error-laden, takes research out of its true context, uses numbers that don’t seem to come from the actual studies, chooses papers testing ivermectin under the least favorable circumstances, gives unexplained and inappropriate weights to the small amount of data that stands as outliers to the bigger picture, and still drives a conclusion of “don’t use this” from a massive average mortality reduction that did not quite reach statistical significance. At the same time the authors consistently complain about the “low quality of evidence” represented by the studies they do and do not include, nearly all of which I would describe as produced by higher quality scientists who can at least tally numbers correctly.

Read More »

PURSUING TRUTH IN COVID DRUG TREATMENT AMID A CENSORED MEDIA LANDSCAPE

The death rate from COVID-19 is dramatically low at United Memorial Medical Center in Houston, TX compared to other hospitals across the nation and the world. Despite Dr. Joseph Varon’s popularity on TV, news personalities avoid questions of why he’s having success treating his patients. As it turns out, he’s using drugs the WHO and CDC recommend against.

Read More »

Hydroxychloroquine and its friends

Dr. Risch gives a succinct history of the politics of hydroxychloroquine and other useful existing medicines in the USA, which has had global effect, as many countries look to the USA for guidance. Corruption and manipulation from behind the scenes around the world are brought to the surface for scrutiny.

Read More »

India Treats Medical Staff Prophylactically and Early, and It Makes a Difference – The Chloroquine Wars Part XXXI

During the first wave, the primary antiviral used was HCQ, and during the second wave (after Facebook censored his account where he was communicating with others in a large nation) they shifted to ivermectin due to HCQ controversies. Similarly to the way Dr. Brian Tyson attacked COVID-19 with an early multi-drug regimen, numerous other medicines, including aspirin, were used. Of Dr. Shah’s 8,000 or so patients, only 5 succumbed to COVID-19. This is notably similar to the results of Dr. Didier Raoult.

Read More »

Institutional Funding of Propaganda Against Early Treatment of COVID-19 – The Chloroquine Wars Part XXX

This is pulled straight from the same playbook as the propaganda against HCQ. Even if you’re not sure that one or both of these medicines is effective despite uniformly positive results when applied as early treatment, you should at least recognize the pattern, scratch your head, and question whether there is…maybe…just possibly some perverse incentive like power or profit from vaccines driving this absurdity.

Read More »

New study reveals success of hydroxychloroquine as COVID treatment

In a new study, Smith and three other medical experts prove what he and this show have been telling you for more than a year that hydroxychloroquine can save lives. Smith’s landmark study followed 255 COVID patients who required intubation during the first two months of the pandemic, and it found that increased doses of coadministered, hydroxychloroquine and azithromycin were associated with a greater than 100% increase in survival.

Read More »

HYDROXYCHLOROQUINE – Observational Study on 255 Mechanically Ventilated Covid Patients at the Beginning of the USA Pandemic

Most Covid studies have not considered days of therapy, cumulative dose, or weight-adjusted dosing. We found that when the cumulative doses of two drugs, HCQ and AZM, were above a certain level, patients had a survival rate 2.9 times the other patients. By using causal analysis and considering of weight-adjusted cumulative dose, we prove the combined therapy, >3 g HCQ and > 1g AZM greatly increases survival in Covid patients on IMV and that HCQ cumulative dose > 80 mg/kg works substantially better. These data do not yet apply to hospitalized patients not on IMV. Since those with higher doses of HCQ had higher doses of AZM, we cannot solely attribute the causal effect to HCQ/AZM combination therapy. However, it is likely AZM does contribute significantly to this increase in survival rate. Since higher dose HCQ/AZM therapy improves survival by nearly 200% in this population, the safety data are moot. However, given the data presented here, the studies reporting HCQ’s effect of QTc intervals need to be re-evaluated.

Read More »

Is the vaccine safe? Undoing the spin on the vaccine. We have safe and effective treatment options for COVID.

Doctors have found safe, effective and inexpensive treatments that work well in preventing and treating patients with COVID-19 like Ivermectin that’s been used safely for more than 30 years.
But the government has not supported the use of this effective drug. In fact, there are other therapies like hydroxychloroquine, vitamins D and C and zinc that physicians have found to be safe and effective in preventing and treating COVID.

Read More »

The Chloroquine Wars Part XXI

Dr. Pierre Kory explain both the case that ivermectin (IVM) effectively prevents or treats COVID-19, and also how and why that information is withheld by public health officials.

Read More »

An Interview with Dr Vladimir Zelenko, MD

We are very honored to present this interview of Dr Vladimir Zelenko, the father of outpatient treatment for COVID-19 in North America. Dr Zelenko shares his own experience with COVID-19 as a patient, as he is recovering from a severe form of the disease.
He also talks about his cancer and how he was able to go through this dramatic episode of his life. Then, he presents his perspectives about outpatient treatment as practiced today and the evolution of the pandemic, among other topics.

Read More »

The Chloroquine Wars Part XVII – Why the Story About India’s April COVID-19 Spike is All Wrong

So, what’s different between Maharashtra and Delhi with respect to the rest of India and South Asia? Instead of relying on HCQ and IVM, many doctors and health officials in Maharashtra and Delhi pushed the expensive and profitable remdesivir drug. Due to its cost and recommended time of usage, remdesivir is not used either as a prophylaxis or for early outpatient treatment. And unlike the cheap and easy-to-produce HCQ and IVM, remdesivir is difficult to replace when it runs out.

Read More »

How much proof do you want? Hundreds of studies conclude – treat Covid-19 early with hydroxychloroquine!

HCQ is effective for COVID-19. The probability that an ineffective treatment generated results as positive as the 235 studies to date is estimated to be 1 in 6 quadrillion (p = 0.00000000000000018).
Early treatment is most successful, with 100% of 29 studies reporting a positive effect (13 statistically significant in isolation) and an estimated reduction of 65% in the effect measured (death, hospitalization, etc.) using a random effects meta-analysis, RR 0.35 [0.25-0.50].
92% of Randomized Controlled Trials (RCTs) for early, PrEP, or PEP treatment report positive effects, the probability of this happening for an ineffective treatment is 0.0017.

Read More »